Drug Profile
Research programme: sigma 1 receptor activators/M1 muscarinic allosteric modulators - Anavex Life Sciences/Life Science Research Israel
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Life Science Research Israel
- Developer Anavex Life Sciences
- Class Antidementias; Antiparkinsonians; Small molecules
- Mechanism of Action Muscarinic M1 receptor modulators; Sigma-2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA
- 08 Apr 2016 ANAVEX 3-71 receives Orphan Drug status for Frontotemporal dementia in USA
- 01 May 2014 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route)